Lunai Bioworks Inc. (LNAI)Healthcare | Biotechnology | Los Angeles, United States | NasdaqCM
2.37 USD
+0.02
(0.851%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.37 |
Hot Take ↕ | Aug. 22, 2026, 3:15 a.m. EDT
The investment case for Lunai Bioworks is effectively nonexistent based on the available data. The company is trapped in a severe multi-year structural decline, having lost over 94% of its value since 2018 with four consecutive years of negative annual returns. Fundamentally, the business is deteriorating rapidly: it generates no revenue, burns cash aggressively, and sits on a negative book value with a precarious liquidity situation highlighted by a current ratio of just 0.19. While recent headlines suggest a reverse split and legal battles against short-sellers, these are often signs of distress rather than recovery. The options market confirms this pessimism, with traders buying deep protection while ignoring upside potential. There is no margin of safety here; the market has already priced in the worst-case scenario of a failing biotech startup with no commercial product yet. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.152242 |
| AutoTheta | 0.154728 |
| AutoETS | 0.155326 |
| MSTL | 0.157549 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.393 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.008 |
| Market Cap | 10,745,319 |
| Beta | 0.32 |
| Previous Name | Enochian Biosciences, Inc. |
| Website | https://www.lunaibioworks.com |
As of Aug. 22, 2026, 3:15 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive implied volatility (775%) and open interest in at-the-money puts compared to negligible call activity. This indicates a market consensus expecting significant further declines rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8711623 |
| Address1 | 2,080 Century Park East |
| Address2 | Suite 906 |
| All Time High | 1,102.4 |
| All Time Low | 1.208 |
| Ask | 2.94 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 30,380 |
| Average Daily Volume3 Month | 973,319 |
| Average Volume | 973,319 |
| Average Volume10Days | 30,380 |
| Beta | 0.318 |
| Bid | 1.73 |
| Bid Size | 2 |
| Book Value | -2.136 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.37 |
| Current Ratio | 0.194 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.435 |
| Day Low | 2.28 |
| Display Name | Lunai Bioworks |
| Earnings Timestamp End | 1,790,625,600 |
| Earnings Timestamp Start | 1,790,625,600 |
| Ebitda | -9,769,810 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.921 |
| Enterprise To Revenue | 429.826 |
| Enterprise Value | 9,001,414 |
| Eps Trailing Twelve Months | -60.37 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.7012 |
| Fifty Day Average Change | -0.33120012 |
| Fifty Day Average Change Percent | -0.122612216 |
| Fifty Two Week Change Percent | -87.11623 |
| Fifty Two Week High | 19.6 |
| Fifty Two Week High Change | -17.23 |
| Fifty Two Week High Change Percent | -0.8790816 |
| Fifty Two Week Low | 1.208 |
| Fifty Two Week Low Change | 1.162 |
| Fifty Two Week Low Change Percent | 0.9619205 |
| Fifty Two Week Range | 1.208 - 19.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,518,013,800,000 |
| Float Shares | 2,922,047 |
| Free Cashflow | -6,964,201 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | 0.02 |
| Fullday Change Percent | 0.851063 |
| Fullday Price | 2.37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 20,942 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.40715 |
| Held Percent Institutions | 0.03532 |
| Implied Shares Outstanding | 4,533,890 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,779,408,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California. |
| Long Name | Lunai Bioworks Inc. |
| Market | us_market |
| Market Cap | 10,745,319 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_549849556 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -128,284,016 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 10,949,344 |
| Open | 2.35 |
| Operating Cashflow | -5,258,315 |
| Operating Margins | -68.152985 |
| Payout Ratio | 0.0 |
| Phone | 305 918 1980 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.37 |
| Post Market Time | 1,787,959,804 |
| Prev Name | Enochian Biosciences, Inc. |
| Previous Close | 2.35 |
| Price Hint | 4 |
| Price To Book | -1.1095506 |
| Price To Sales Trailing12 Months | 513.099 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.164 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 0.851063 |
| Regular Market Day High | 2.435 |
| Regular Market Day Low | 2.28 |
| Regular Market Day Range | 2.28 - 2.435 |
| Regular Market Open | 2.35 |
| Regular Market Previous Close | 2.35 |
| Regular Market Price | 2.37 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 35,205 |
| Return On Assets | -0.096470006 |
| Return On Equity | -3.25456 |
| Revenue Per Share | 0.008 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,533,890 |
| Shares Percent Shares Out | 0.0344 |
| Shares Short | 155,986 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 121,746 |
| Short Name | Lunai Bioworks Inc. |
| Short Percent Of Float | 0.0394 |
| Short Ratio | 0.38 |
| Source Interval | 15 |
| State | CA |
| Symbol | LNAI |
| Total Cash | 3,155,272 |
| Total Cash Per Share | 0.696 |
| Total Debt | 1,411,367 |
| Total Revenue | 20,942 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -60.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.485615 |
| Two Hundred Day Average Change | -2.115615 |
| Two Hundred Day Average Change Percent | -0.47164434 |
| Type Disp | Equity |
| Volume | 35,205 |
| Website | https://www.lunaibioworks.com |
| Zip | 90,067 |